123 related articles for article (PubMed ID: 9509307)
1. Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis.
Ikeda E; Hikita N; Eto K; Mochizuki M
Jpn J Ophthalmol; 1997; 41(6):396-402. PubMed ID: 9509307
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats.
Kawashima H; Fujino Y; Mochizuki M
Invest Ophthalmol Vis Sci; 1988 Aug; 29(8):1265-71. PubMed ID: 2458329
[TBL] [Abstract][Full Text] [Related]
3. Prevention of experimental autoimmune uveoretinitis by intrathymic S-antigen injection.
Koevary SB; Caspi RR
Ocul Immunol Inflamm; 1997 Sep; 5(3):165-72. PubMed ID: 9326761
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis.
Martin DF; DeBarge LR; Nussenblatt RB; Chan CC; Roberge FG
J Immunol; 1995 Jan; 154(2):922-7. PubMed ID: 7814893
[TBL] [Abstract][Full Text] [Related]
5. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes.
Zhang R; He R; Qian J; Guo J; Xue K; Yuan YF
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3575-82. PubMed ID: 20164461
[TBL] [Abstract][Full Text] [Related]
6. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction.
Roberge FG; Xu D; Chan CC; de Smet MD; Nussenblatt RB; Chen H
Curr Eye Res; 1993 Feb; 12(2):197-203. PubMed ID: 8449029
[TBL] [Abstract][Full Text] [Related]
7. T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis.
Prendergast RA; Iliff CE; Coskuncan NM; Caspi RR; Sartani G; Tarrant TK; Lutty GA; McLeod DS
Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):754-62. PubMed ID: 9538882
[TBL] [Abstract][Full Text] [Related]
8. Suramin treatment suppresses induction of experimental autoimmune uveoretinitis (EAU) in rodents.
Sartani G; Silver PB; Strassmann G; Chan CC; Caspi RR
Curr Eye Res; 1995 Oct; 14(10):887-96. PubMed ID: 8549154
[TBL] [Abstract][Full Text] [Related]
9. Everolimus improves experimental autoimmune uveoretinitis.
Hennig M; Bauer D; Wasmuth S; Busch M; Walscheid K; Thanos S; Heiligenhaus A
Exp Eye Res; 2012 Dec; 105():43-52. PubMed ID: 23059401
[TBL] [Abstract][Full Text] [Related]
10. Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific.
Laliotou B; Liversidge J; Forrester JV; Dick AD
Br J Ophthalmol; 1997 Jan; 81(1):61-7. PubMed ID: 9135411
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of intravitreal administration of tresperimus, an immunosuppressive drug, on experimental autoimmune uveoretinitis.
Bousquet E; Camelo S; Leroux les Jardins G; Goldenberg B; Naud MC; Besson-Lescure B; Lebreton L; Annat J; Behar-Cohen F; de Kozak Y
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5414-23. PubMed ID: 21666239
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
[TBL] [Abstract][Full Text] [Related]
13. Effects of systemic and intravitreal TNF-α inhibition in experimental autoimmune uveoretinitis.
Busch M; Bauer D; Hennig M; Wasmuth S; Thanos S; Heiligenhaus A
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):39-46. PubMed ID: 23211816
[TBL] [Abstract][Full Text] [Related]
14. Orally induced bystander suppression in experimental autoimmune uveoretinitis occurs only in the periphery and not in the eye.
Wildner G; Thurau SR
Eur J Immunol; 1995 May; 25(5):1292-7. PubMed ID: 7774632
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis.
Camelo S; Lajavardi L; Bochot A; Goldenberg B; Naud MC; Brunel N; Lescure B; Klein C; Fattal E; Behar-Cohen F; de Kozak Y
J Ocul Pharmacol Ther; 2009 Feb; 25(1):9-21. PubMed ID: 19232006
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat.
Kawashima H; Fujino Y; Mochizuki M
Invest Ophthalmol Vis Sci; 1990 Dec; 31(12):2500-7. PubMed ID: 1702408
[TBL] [Abstract][Full Text] [Related]
17. Suppression of experimental uveitis with monoclonal antibodies to ICAM-1 and LFA-1.
Uchio E; Kijima M; Tanaka S; Ohno S
Invest Ophthalmol Vis Sci; 1994 Apr; 35(5):2626-31. PubMed ID: 7909311
[TBL] [Abstract][Full Text] [Related]
18. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
Kohno H; Sakai T; Saito S; Okano K; Kitahara K
Exp Eye Res; 2007 Mar; 84(3):569-76. PubMed ID: 17208229
[TBL] [Abstract][Full Text] [Related]
19. LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells.
Cunningham MA; Austin BA; Li Z; Liu B; Yeh S; Chan CC; Anglade E; Velagaleti P; Nussenblatt RB
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):249-55. PubMed ID: 18708627
[TBL] [Abstract][Full Text] [Related]
20. Resident and infiltrating immune cells in the uveal tract in the early and late stages of experimental autoimmune uveoretinitis.
Butler TL; McMenamin PG
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2195-210. PubMed ID: 8843906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
